Navigation Links
Tobacco company misrepresented danger from cigarettes
Date:1/6/2012

A new UCSF analysis of tobacco industry documents shows that Philip Morris USA manipulated data on the effects of additives in cigarettes, including menthol, obscuring actual toxicity levels and increasing the risk of heart, cancer and other diseases for smokers.

Tobacco industry information can't be taken at face value, the researchers conclude. They say their work provides evidence that hundreds of additives, including menthol, should be eliminated from cigarettes on public health grounds.

The article is published in PLoS Medicine http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001145

In the new, independent study, the scientists reassessed data from Philip Morris' "Project MIX," which detailed chemical analyses of smoke and animal toxicology studies of 333 cigarette additives. Philip Morris, the nation's largest tobacco company, published its findings in 2002.

By investigating the origins and design of Project MIX, the UCSF researchers conducted their own inquiry into the Philip Morris results. They stressed that many of the toxins in cigarette smoke substantially increased after additives were added to cigarettes.

They also found, after obtaining evidence that additives increased toxicity, that tobacco scientists adjusted the protocol for presenting their results in a way that obscured these increases.

"We discovered these post-hoc changes in analytical protocols after the industry scientists found that the additives increased cigarette toxicity by increasing the number of fine particles in the cigarette smoke that cause heart and other diseases," said senior author Stanton A. Glantz, PhD, UCSF professor of medicine and director of the Center for Tobacco Control Research and Education at UCSF.

"When we conducted our own analysis by studying additives per cigarette following Philip Morris' original protocol -- we found that 15 carcinogenic chemicals increased by 20 percent or more," he said.

Additionally, in the independent study, the researchers discovered the reason behind Philip Morris' failure to identify many toxic effects in animal studies: its studies were too small.

"The experiment was too small in terms of the number of rats analyzed to statistically detect important changes in biological effects," Glantz said. "Philip Morris underpowered its own studies."

The results of "Project MIX" were first published as four papers in a 2002 edition of Food and Chemical Toxicology, a journal whose editor and many members of its editorial board had financial ties to the tobacco industry. While Philip Morris was trying to get the papers published, the company scientist who led Project Mix sent an email to a colleague describing the peer review process as "an inside job." http://legacy.library.ucsf.edu/tid/ekw86a00/pdf?search=%22inside%20job%20philip%20morris%20project%20mix%20email%22

In the new study, the researchers used documents made public as a result of litigation against the tobacco industry. The documents are available to the public through UCSF's Legacy Tobacco Documents Library.


'/>"/>
Contact: Elizabeth Fernandez
elizabeth.fernandez@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. New report identifies research needed on modified risk tobacco products
2. UCSF to receive tobacco papers, funding to improve public access to the documents
3. States could see substantial savings with tobacco control programs
4. UIC awarded $14 million to study tobacco pricing and media
5. National Study Will Track Tobacco Use in U.S.
6. FDA and NIH announce joint study on tobacco use and risk perceptions
7. Big Tobacco knew radioactive particles in cigarettes posed cancer risk but kept quiet
8. Stronger tobacco control policy in the Netherlands would save thousands of lives
9. UCSF, UC Merced to study effectiveness of anti-tobacco programs
10. Effects of tobacco use among rural African American young adult males
11. Illegal Tobacco Sales to U.S. Minors Reach All-Time Low
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tobacco company misrepresented danger from cigarettes
(Date:8/17/2017)... ... August 17, 2017 , ... ... Wednesday, August 16, to community partners. The newly renovated ER was designed with ... for minor emergencies, eight semi-private rooms to deliver patient results, improve efficiencies and ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on ... inner healing of memories and achieve forgiveness, through a progressive journey toward healing. ...
(Date:8/17/2017)... ... , ... Advice Media, the industry leader in digital marketing for medical practices, has been recognized ... included in the Inc. 5000 for the second time in two years. Shawn Miele, Chief ... 5000 rankings for the second year in a row. It’s extremely difficult to make this ...
(Date:8/16/2017)... ... ... Summer days spent with family are priceless. Since August is Family Fun Month, ... season of sunshine. Add trying something new to this summer’s bucket list. Whether it’s ... fun. , Try Something New , Choose an activity the whole ...
(Date:8/16/2017)... ... ... Ten outstanding teachers in the Greater Houston area will be named one ... by a Houston Texans player, two tickets to a Texans game, and other prizes. ... texanschecking.com/stars to nominate their favorite teacher with an essay of no more than 500 ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology: